The underperformance of J&J's Medical Devices segment, and particularly its orthopaedic product lines, has been the root of the company's slow growth in recent times. J&J must be proactive with the cash the restructuring will provide and balance boosting its bottom line with top line investment. Investor sentiment indicates the restructuring may be too little, too late.
Complete the trial form to receive a free issue of Corporate Financing Week sent to your email address. Giving you analysis of the latest corporate financing trends and deals
START A FREE TRIAL TODAY
STEP 2: SELECT PRODUCTS
Please select the free products you would like to trial:
Thank you for your interest in Corporate Financing Week
You will shortly receive an e-mail with link(s) to a full version of the newsletter(s) you selected. A member of our Client Services team will be in touch soon to receive your feedback on the newsletters and arrange a convenient time for a free demonstration of the full service. If your enquiry is urgent, please email our team here Thanks, BMI Research